Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | PLK4 | O00444 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.38 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.38 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16316641 | 0.93 | CDC7 (0.35) | CDC7PLK4AURKADAPK3ROCK2 | |
| SCHEMBL22792919 | 0.76 | CDC7 (0.36) | CDC7PLK4AURKADAPK3ROCK2 | |
| SCHEMBL30744214 | 0.71 | TRPM5 (0.43) | CDC7PLK4AURKADAPK3ROCK2 | |
| SCHEMBL22304348 | 0.70 | CDC7 (0.36) | CDC7PLK4AURKADAPK3ROCK2 | |
| SCHEMBL12228891 | 0.70 | DYRK1A (0.38) | PGR | |
| SCHEMBL12228845 | 0.70 | TDO2 (0.35) | — | |
| SCHEMBL18421462 | 0.68 | PGR (0.46) | PGR | |
| SCHEMBL22304357 | 0.67 | TRPM5 (0.33) | CDC7PLK4AURKADAPK3ROCK2 | |
| SCHEMBL12228882 | 0.66 | DYRK1A (0.38) | CSNK1DPGR | |
| SCHEMBL16316636 | 0.66 | PGR (0.33) | PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293527-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230293527-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11724987-B2 | Compositions and methods of treating retinal disease | ALDEYRA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230248727-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230248727-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-11583529-B2 | Treatment of inflammatory disorders | ALDEYRA THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220133697-A1 | INJECTABLE FORMULATIONS | ALDEYRA THERAPEUTICS, INC. | 2022-05-05 | — | — | US | disclosed |
| US-20210353628-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2021-11-18 | — | — | US | disclosed |
| US-11040039-B2 | Treatment of inflammatory disorders | ALDEYRA THERAPEUTICS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-10913722-B2 | Compositions and methods of treating retinal disease | ALDEYRA THERAPEUTICS, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-9364471-B2 | Compositions and methods of treating retinal disease | ALDEYRA THERAPEUTICS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9265759-B2 | Compositions and methods of treating retinal disease | ALDEYRA THERAPEUTICS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150209333-A1 | COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2015-07-30 | — | — | US | disclosed |
| US-20150209345-A1 | COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2015-07-30 | — | — | US | disclosed |
| US-8940721-B2 | Compositions and methods of treating retinal disease | ALDEXA THERAPEUTICS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940764-B2 | Compositions and methods of treating retinal disease | ALDEXA THERAPEUTICS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20110263645-A1 | Compositions and Methods of Treating Retinal Disease | NEURON SYSTEMS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-7973025-B2 | Compositions and methods of treating retinal disease | NEURON SYSTEMS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20090182009-A1 | Compositions and methods of treating retinal disease | NEURON SYSTEMS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-20070135481-A1 | Compositions and methods of treating retinal disease | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209345-A1 | COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE | ALDH1A2, CLN6, PLA2G2E | CDC7 4761/4885PLK4 4353/4885AURKA 4834/4885 |
| US-20090182009-A1 | Compositions and methods of treating retinal disease | ALDH1A2, PLA2G2E, CLN6 | CDC7 4779/4885PLK4 4308/4885AURKA 4823/4885 |
| US-11040039-B2 | Treatment of inflammatory disorders | TNF, NFKBIA, LTB4R2 | CDC7 4590/4885PLK4 3486/4885AURKA 4849/4885 |
| US-11724987-B2 | Compositions and methods of treating retinal disease | ALDH1A2, PLA2G2E, CLN6 | CDC7 4779/4885PLK4 4308/4885AURKA 4823/4885 |
| US-20230293527-A1 | TREATMENT OF INFLAMMATORY DISORDERS | TNF, NFKBIA, LTB4R2 | CDC7 4590/4885PLK4 3486/4885AURKA 4849/4885 |
| US-11583529-B2 | Treatment of inflammatory disorders | TNF, NFKBIA, LTB4R2 | CDC7 4590/4885PLK4 3486/4885AURKA 4849/4885 |
| US-20220133697-A1 | INJECTABLE FORMULATIONS | ALDH2, CLN6, ALDH1A1 | CDC7 4884/4885PLK4 3993/4885AURKA 4744/4885 |
| US-10913722-B2 | Compositions and methods of treating retinal disease | ALDH1A2, CLN6, PLA2G2E | CDC7 4761/4885PLK4 4353/4885AURKA 4834/4885 |
| US-20150209333-A1 | COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE | ALDH1A2, PLA2G2E, CLN6 | CDC7 4779/4885PLK4 4308/4885AURKA 4823/4885 |
| US-20210353628-A1 | TREATMENT OF INFLAMMATORY DISORDERS | TNF, NFKBIA, LTB4R2 | CDC7 4590/4885PLK4 3486/4885AURKA 4849/4885 |
| US-20070135481-A1 | Compositions and methods of treating retinal disease | ALDH1A2, PLA2G2E, CLN6 | CDC7 4779/4885PLK4 4308/4885AURKA 4823/4885 |
| US-20230248727-A1 | TREATMENT OF INFLAMMATORY DISORDERS | TNF, NFKBIA, LTB4R2 | CDC7 4590/4885PLK4 3486/4885AURKA 4849/4885 |
| US-20110263645-A1 | Compositions and Methods of Treating Retinal Disease | ALDH1A2, CLN6, PLA2G2E | CDC7 4761/4885PLK4 4353/4885AURKA 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.